Teemu Junttila, PhDPrincipal Scientist, Translational Oncology at Genentech
Profile
Dr. Junttila joined Genentech in 2006. Currently his research is focused in developing Genentech’s T cell dependent bispecific (TDB) antibodies and he is responsible of multiple CD3-bispecific molecules in various stages, ranging from early stage research to clinical development.
Agenda Sessions
A Biological Rationale for Toxicity Mitigation with CD3 Bispecifics
On DemandView SessionLIVE Moderated Panel Discussion and Q&A Including Audience Interaction with Speakers from On-Demand SESSION #5: BISPECIFIC ANTIBODIES: NEW APPROACHES AND CASE STUDIES - To prepare for this discussion/Q&A, attendees should view the presentations from Session #5 in the Watch On-Demand Sessions Tab prior to this session
15:45View Session